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1. INTRODUCTION  
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1.1. Pain 
Conferring to the taxonomy of International Association for the Study of Pain (IASP), 
pain is defined as an „unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage“ (1). Pain is an individual feeling 
that each individual understands to express through different experiences in early life. From a 
neurobiological standpoint pain is divided in three different categories: nociceptive pain, 
inflammatory pain and pathological pain (2). 
Nociceptive pain is an early-warning system crucial to stimulate the withdrawal reflex 
to protect oneself from damaging or noxious stimuli. The second type of pain is inflammatory 
pain which is connected with tissue damage and the infiltration of immune cells. It reduces 
further risk of damage and promotes recovery by causing hypersensitivity to pain until healing 
occurs. The final type is pathological pain, which does not protect but is maladaptive and results 
from abnormal functioning of the nervous system rather than from actual tissue damage. 
Pathological pain is caused by conditions in which no damage of inflammation is the cause but 
is provoked by damage to the nervous system. This is why it can be divided in neuropathic 
pain and dysfunctional pain (2). 
Temporal classification divides pain into acute and chronic. It is considered that acute pain 
lasts up to three months, and chronic pain more than three months. As acute pain is self-limited 
and serves a biologic purpose, chronic pain could be considered a disease state. It endures the 
normal period of healing or develops from psychological states and has neither biologic 
purpose nor an identifiable end-point (3). Chronic pain is main cause of suffering and disability 
worldwide, and a usual symptom of many diseases that interfere with life quality (4). 
As pain has an intense influence on the quality of life it can have physical, psychological 
and social effects (5). Because of that, according to the international human rights law, 
countries are obliged to provide pain treatment medications under the right to health (5) 
 
1.2. Hierarchy of evidence based medicine 
 In order to make decisions about the care and health of patients, evidence-based 
medicine is the key to refer on. It is the careful, precise, wise and rational use of new and 
modern use of making decision about management of patients (6). 
 Evidence based medicine combines clinical experience of healthcare workers and 
patient values with the best available research information. The aim is to increase the quality 
3 
 
of using scientific research in making decisions in clinical settings. For healthcare workers it 
is crucial to be skilled in literature-searching and evidence appraisal so that they can 
incorporate best available evidence in their clinical practice (6). 
 A great benefit of evidence-based medicine has been the development of systematic 
reviews and meta-analyses, methods where multiple studies on a topic were identified, then the 
best ones are evaluated to analyze them in a robust and rigorous way to create a summary of 
the best available evidence (6). 
 Evidence-based medicine classifies different types in a hierarchical system of clinical 
evidence and is then classified conferring to the potency of their choice from the various biases 
that affected medical research (6). 
 Level 1 stands for evidence obtained by meta-analysis of several randomized controlled 
trials (RCTs). Evidence from only one RCT is considered as level 1b while evidence from well-
designed controlled trial is level 2a. Furthermore, evidence from one experimental research are 
level 2b. The next is level 3, which contains evidence from non-experimental studies as 
comparative research or case studies, according to for example textbooks. Evidence based 
solely on expert opinion and impressions from clinical practice are described as level 4 (6). 
 Clinicians are encouraged to find the highest level of evidence to answer clinical 
questions. To facilitate the search for relevant data, papers are assigned a level of evidence to 
specify their strength of recommendation. The grading system used may be different depending 
on the publishing journal, but most allocate 4 or 5 levels, level 1 being the most recommended. 
Obviously, this does not mean that all level 1 evidence should be accepted as fact, or that all 
level 4 evidence should be unnecessary. The ranking should be taken as a direction when 
interpreting study results (7). 
 Nowadays, it is expected that all physicians in western countries apply evidence-based 
medicine in management for every patient, which is supported by the governments of these 
countries, the ministries of health and pharmaceutical industry. This practice incorporates 
evidence-based clinical guidelines for different diseases, which is a database with the best 
given evidence from each category that is updated every day with the newest information (6).  
 The Centre for Evidence Based Medicine (CEBM) states that the most reliable evidence 
is found in systematic reviews, types of research that summarize evidence from other studies. 
To the contrary, the least reliable sources are case series studies and expert opinions, because 
they often contain the authors’ personal experiences and opinions (7). 
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1.3. Randomized controlled trials 
 RCTs are considered as highest-ranking primary studies in the hierarchy of evidence in 
medicine. RCTs can be used to study interventions that prevent or treat a disease. They are 
vital for evidence-based medicine as they are the gold standard for studying efficacy and safety 
of new treatments (8). 
 One decisive advantage of RCTs over non-randomized studies for the evaluation of 
therapeutic procedures is randomization which gives participants equal opportunity that they 
will be in any of the RCT arms. When starting an RCT the population is sampled and randomly 
assigned into either experimental or control group. By this distribution, systematic differences 
between groups in factors are prevented, whether known or unknown, that may affect the 
outcome. Therefore, it is expected that the groups show the same number of desired or 
undesired events over the study period, assumed they received the same treatment (9). 
 Typical features of RCTs are that all intervention groups are treated equal except of the 
experimental treatment and the intention-to-treat analysis what means that all participants are 
analyzed within their allocated group irrespective of whether they experience the intended 
intervention (10). To ensure a standard of a high quality RCT, the choice of study question and 
design plays an important role, as well as the prevention of systematic errors. Bias in RCTs is 
of great importance, and therefore planning of trial has to be very meticulous in order to avoid 
bias, because bias easily falsifies the results and may decrease the level of evidence. This can 
be circumvented by proper randomization of the study population, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessors, making sure that all data 
planned in the protocol are reported, that all participants lost to follow-up are accounted for, 
and that there are no other known sources of bias (10). 
 Another big advantages of RCT study design are the high level of proof provided and 
the ability to study several outcomes at once. On the other hand the amount of time that needs 
to be spent and the costs that it takes to complete a RCT is a major disadvantage. Therefore the 
researcher has to be aware of the necessity of the results at the end of the study and the costs 
that will emerge (10). Other disadvantages are the need for compliance of the participants. Also 
the possibility of a non-representative study population and patient comorbidities are factors 
that need to be considered. RCTs are limited by ethical and practical concerns. The researcher 
should always question him whether the intervention is likely to be beneficial. It is important 
to know if the treatment is developed well enough to permit evaluation (10). 
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 Only the experimental group will be able to receive the therapeutic or preventive 
treatment being investigated. The control group contrary will receive the gold standard 
treatment, or even a placebo or no treatment at all (8). 
 By blinding study participants and if double blinding also the researcher are unaware 
of the assigned intervention. Double blinding is of advantage, in studies where the outcome 
may be influenced if the researcher knows about the distribution of experimental - or control 
group and of what participants are receiving (11). 
 Ethical and legal requirements are equally important. The researcher has to create a 
planned RCT protocol describing the choice topic's background, risk-benefit assessment, study 
design and methods and analysis. The analysis in RCT is aimed on approximating the size of 
the alteration in predefined outcomes between the study arms (11). 
 Latest discussions in worldwide scientific communities, which regulate the use of drugs 
and medical devices, show that RCTs are still the standard for validating efficacy and safety 
so that a new management and intervention can be accepted for use in patients (11). 
 
1.4. Reporting of sex/gender and race/ethnicity in trials 
 Importance of the role of sex and ethnicity in pathology, diagnosis, prevention and 
treatment of diseases has been increasingly emphasized in the scientific community. This 
increased attention to sex-related differences apparently has led to modest increase of inclusion 
of both sexes and reporting of sex-specific analyses in randomized controlled trials (RCTs). 
Analysis conducted in trials published in nine prominent medical journals in 2009 showed that 
median proportion of women in trials that included both men and women was 37% (12). In 
2016 such analysis of trials published in two prominent journals showed that this proportion 
was 41% (13). A 2009 study showed that 75% of trials did not have any outcome analyses 
based on sex (12), while the 2016 study did not find a single trial that had pre-specified  analysis 
of differences by sex (13). 
Similar lack of attention to race/ethnicity was found. A 2009 study indicated that 21% of trials 
did not report race or ethnicity of their sample, and 64% did not do any analyses based on 
race/ethnicity (12). In the field of pain, influence of sex on experimentally-induced pain and 
pain sensitivity is still the subject of debate (14,15). 
However, lack of attention to sex-related reporting in clinical trials about pain has been noted 
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in recent literature. A systematic review about sex differences in the efficacy of psychological 
therapies for treatment of chronic and recurrent pain in children and adolescents found that not 
a single study published on the subject reported outcome data separately by sex. So, systematic 
review authors contacted authors of 46 included studies and 17 studies provided data (16). The 
review conclusion was that future studies need to examine whether mechanisms of treatment 
efficacy differ between sexes, and consider the impact of pre-treatment sex differences on 
response to treatment (16). Insufficient reporting of sex effects was also found for systematic 
reviews about chronic pain (17). 
 Multiple studies in the past have already shown that there is a high amount of chronic 
pain states and greater pain sensitivity among females compared to males. Pain is thought to 
be mediated by many different compounds. Therefore the sex differences should be 
emphasized (18). A factor that also needs to be included are sex hormones. They play a big 
role in the influence of pain sensitivity. Especially the menstrual cycle in females changes the 
threshold and tolerance of pain (18).  
 Likewise, many studies reported that race/ethnicity is associated with important 
differences between patients when it comes to pain. For this reason, race/ethnicity should be 
reported among the baseline characteristics of patients and, when feasible, outcomes should 
also be reported per race/ethnicity so that we can gain more insight into potential differences 
in the effect of interventions related to race/ethnicity (19–21). The important role of 
comorbidities in different races was shown in hospital readmission. It presented that there are 
higher rates of readmission in black people than in white associated with chest pain. That leads 
to the suggestion that biological and genetic factors play a role in racial disproportions.  
That gene variations could lead to bigger problems as it has to be known that many diseases 
show different signs and symptoms and are expressed differently intensity in different races. 
Therefore it might be that the patient has to be individually treated by taking this fact into 
account (20). 
 Regarding diseases and their symptoms and outcomes it is necessary to report about the 
gender distribution. For example, it is shown that women in early stages of coronary artery 
disease present with symptoms such as fatigue, abdominal discomfort, back pain or neck pain. 
The problem here is that all of those symptoms are considered to be atypical, as those are 
standards which were mainly researched on men (22). Furthermore, usual tests that are used 
for diagnosis, like electrocardiography and radionucleotide myocardial perfusion imaging are 
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not as sensitive to detect coronary artery disease in women as in men. Studies on mice about 
gene constitution, presented different expression of genes in multiple tissues that are differently 
manifested in males than in females. Additionally there are hereditary differences of hormonal 
action depending if the mother or the father inherits it (22).  
Clinical experience shows that men and women react differently on certain drugs and 
medication. One crucial example is that anesthesiologists found out that women awake much 
faster from sedation from propofol then men. On the other hand men have a shorter recovery 
time whereas women are more prone to get side effects like nausea and vomiting or headache. 
This is why anesthesiologists had to learn to calculate the dosage taking into account patients 
gender and the women’s stage of menstrual cycle (22). 
These circumstances warrant increased scrutiny of gender-based bias in clinical 
research. Otherwise women will face the problem of getting therapies, which may not be of the 
same benefit as they are for men (22). 
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2. OBJECTIVES  
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The aim of this study was to assess reporting of data on sex and race/ethnicity in RCTs of 
interventions published in the highest-ranking journals from the field of anaesthesiology from 
2014 to 2017. Specific aims of the study were to analyse  
(i) whether stratiﬁcation based on sex and race/ethnicity was specified in methods,  
(ii) the proportion of women vs men participants included,  
(iii) the proportion of participants of different ethnicity included,  
(iv) whether sex-related or race/ethnicity-related results were reported (either as a 
subgroup analysis for any outcome, or as a covariate in modeling),  
(v) whether there was any difference in efficacy of tested interventions related to sex 
and race/ethnicity and  
(vi) whether sex-related or race/ethnicity results were addressed in Discussion. 
 
 
The hypotheses for the analysed cohort of trials were: 
(i) less than 10% of analyzed trials will include stratification based on sex and 
race/ethnicity 
(ii) proportion of included women will be significantly lower compared to proportion 
of men 
(iii) less than 10% of analyzed trial reported information about participants’ ethnicity 
(iv) sex-related or race/ethnicity-related results were reported in less than 10% of 
analyzed trials 
(v) if tested, majority of trails will show significant differences in efficacy of tested 
interventions related to sex and race/ethnicity 
(vi) less than 10% of analyzed trials addressed sex-related or race/ethnicity in 
Discussion. 
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3. MATERIALS AND METHODS  
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3.1. Study design 
This was a cross-sectional meta-epidemiological study of RCTs published in peer-
reviewed journals. We conducted only analysis of publicly available secondary data; personal 
patient data were not included and therefore approval of an Ethics committee was not 
necessary. 
 
3.2. Inclusion and exclusion criteria 
We included RCTs of interventions that were published during the most recent full four 
years in the first-quartile journals indexed in the Journal Citation Reports (JCR) category 
Anesthesiology. Based on the 2016 JCR impact factor those seven journals were (in alphabetic 
order) Anaesthesia, Anesthesia and Analgesia, Anesthesiology, Pain, British Journal of 
Anaesthesia, European Journal of Anaesthesiology, Regional Anesthesia and Pain Medicine. 
 
3.3. Search 
We searched MEDLINE using advanced search feature with a journal name, filter for 
trials and filter for the chosen dates. We exported bibliographic records (titles and abstracts) of 
search results to EndNote X5 (Clarivate Analytics) reference management software. The 
authors independently screened titles/abstracts and full texts if necessary against inclusion 
criteria. Any disagreements were resolved via discussion. Full texts of included trials were 
downloaded for data extraction. 
 
3.4. Data extraction 
We used Microsoft Excel (Microsoft Inc., Redmond, WA, USA) to prepare data 
extraction sheets, which were piloted on ten first studies for consistency and clarity. We 
extracted the following data: name of the study, year of publication, journal name, availability 
of stratification based on sex and race/ethnicity in methods, number of men and women 
enrolled, number of members of different race/ethnicity enrolled, pre-specification of sex-
related or race/ethnicity related analyses in methods, presence of sex-related or race/ethnicity 
related analyses in results, type of analysis planned, type of analysis reported, numerical data 
about differences in efficacy of tested interventions related to sex and race/ethnicity and 
presence of information about sex-related or race/ethnicity results in discussion. We explored 
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temporal trends to see whether any of the analyzed data occurred with higher frequency in the 
more recent years over the analyzed period. 
 
3.5. Data analysis 
We used MedCalc statistical software, v 15.2.1 (MedCalc Software bvba, Ostend, 
Belgium) to conduct data analysis. We presented descriptive statistics data as frequencies and 
percentages. 
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4. RESULTS  
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We analyzed 657 RCTs published between 2014 and mid-2017. The majority of RCTs 
were published in the journal Anesthesia & Analgesia (N=124, 19%), followed by British 
Journal of Anesthesiology (N=105, 16%), Pain (N=102, 16%), Anesthesiology (N=95, 14%), 
Anaesthesia (N=86, 13%), European Journal of Anaesthesiology (N=83, 13%) and Regional 
Anaesthesia and Pain Medicine (N=62, 9 %). 
In our sample of RCTs there were 82 (12%) trials that specified they included 
exclusively women or men: 61 of which indicated they included only women and 21 included 
only men. Among those 61 studies that included women only there were 26 related to 
pregnancy and childbirth, 3 about mastectomy, 16 about gynecological surgeries. The rest of 
16 trials that included exclusively women only mentioned that men were not included without 
a specific reason. 
Among 22 studies that specified they included only men there was 1 article about 
opioid- induced hyperalgesia, where authors stated that the reason for excluding women is due 
to variations during female menstrual cycle, 1 article was about hypospadias of the male 
urethra, 1 paper focused on prostatectomy and all the other 19 men-specific trials did not 
declare a specific reason for that. 
 
4.1. Terminology 
When we analyzed sex vs. gender terminology, 253 (36%) trials mentioned one of these 
two words. Among them, 177 (75%) used word sex, while 61 (25%) used word gender. Not a 
single trial used both of those words in the manuscript. 
Terminology used in the analyzed trials for men was: male (N=427, 65%), men (N=20, 
3%), or the authors simply used letter M (N=32, 5%), while men-related words were not used 
in 177 trials (27%). 
Terminology used for women in trials was: female (N=417, 63%), women (N=55, 8%), 
or just letter F (N=30, 5%); in 172 trials (23%) authors did not use any words related to women. 
 
4.2. Reporting and analyzing sex/gender 
In 18 (2.7%) studies the authors mentioned sex/gender terms in 
Background/Introduction section of the manuscript. In 53 (8%) studies the authors mentioned 
sex/gender terms in Inclusion/exclusion criteria. Analyses of sex/gender was planned in 
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Methods in 32 (5%) of the analyzed trials. In 52 (7.9%) trials authors reported in Results data 
for at least one analyses related to sex/gender. There were 27 (4%) trials that mentioned 
sex/gender in the Discussion section.  
 
4.3. Reporting race/ethnicity 
Regarding the analyses of reporting the race or ethnicity of the patients, we found out 
that out of 657 trials, authors of 59 (9%) mentioned participants’ race or ethnicity anywhere in 
the manuscript. In 3 (0.4%) of studies the authors mentioned race/ethnicity in 
Background/Introduction section. In 6 (0.9%) trials the authors mentioned race/ethnicity in 
inclusion/exclusion criteria. There were 5 (1%) trials that planned any analyses related to 
race/ethnicity in Methods. In 8 (1.2%) trials authors reported any kind of analyses about 
race/ethnicity in the Results section, whereas 5 (1%) of trials mentioned anything related to 
race/ethnicity in their Discussion section. 
 
4.4. Proportion of women and men in trials that included both sexes 
Among 657 RCTs, there were 417 (63%) that included both men and women and 
reported number of participants according to sex. In those trials, on average, there were 49% 
(range: 2.1 to 98%) of men and 51% (range: 2.5 to 98%) of women. Since there were 82 trials 
that specified they included only participants of one sex, there were 158 (24%) trials that either 
did not report whether they included both women and men, or they did not report number of 
women and men in a trial. 
 
4.5. Proportion of race/ethnicity 
There were 59 (9%) of trials that reported any information about proportion of 
participants according to race/ethnicity. Three among them included only white participants, 
and one included only African American participants. In 34 of those 59 trials participants 
belonged to three or more races; 5 included white and African American participants. In 15 
trials authors mentioned that some participants belonged to certain race/ethnicity, but without 
specifying this information for the remaining participants. In one study the authors indicated 
that the participants were born in Denmark, but without information about race/ethnicity. 
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Average percent of white participants in the 59 studies that reported any information 
about race/ethnicity was 74% (range: 2.4% to 100%). In 6 (10%) out of 59 studies the reported 
number of participants of different race/ethnicity did not match the total number of included 
participants; therefore, the authors have probably made mistakes while listing the number of 
participants of different race/ethnicity. 
 
4.6. Results of sex-based analyses, and race/ethnicity-based analyses 
In 52 (7.9%) trials that reported results of sex-based analyses in Results, 20 (38%) 
described that there was a significant difference between women and men in at least one 
analyzed outcome. Table 1 shows examples of results that explored study outcomes in the 
context of sex/gender. Among 8 trials that reported results based on race/ethnicity, 1 (12.5%) 
trial reported significant difference in at least one analyzed outcome for participants of different 
race/ethnicity. There were no trials that reported stratification of participants according to the 
sex/gender or race/ethnicity. Examples of reported results for study outcomes according to the 
race/ethnicity are shown in Table 2. 
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Table 1. Example of results reported for analyses related to sex/gender 
 
Results Significant difference 
based on sex/gender? 
A Cox proportional hazards model for the time to the first analgesic 
request was performed including the following variables: 
dexamethasone dose, sex, age and type of surgery. None of the 
variables except dose of dexamethasone was significant (Fig. 2). 
No 
Additionally, analyses were conducted in both the TKR and THR 
cohort to explore the interaction of gender with preoperative pain 
severity, change in pain severity, PPTs and preoperative pain severity, 
and PPTs and change in pain severity. No strong evidence of an 
interaction was observed (data not shown). 
No 
Factors that were not associated with posterior vessel wall puncture 
included sex, experience in practice, specialty, and the number of 
ultrasound-guided vascular access procedures performed or 
supervised (table 2). 
No 
Among the 67 patients in Group I, 11 men and two women received 
IOC versus 18 men and 20 women among the 71 patients in Group C. 
There were statistically significant effects of mobilisation on both 
men and women, but more men than women in Group I required 
IOC (P<0.04). 
Yes 
Analyses of SPID48 based on sex, age, body mass index (BMI), and 
type of surgery were statistically significantly greater for SSTS 
compared with placebo for all subgroups (P < 0.001; table 2). 
Yes 
At mid levels, significant predictors were BMI, sex and intervertebral 
space (R2=0.21; P<0.001), whereas at low levels only weight as 
significant (R2=0.34; P<0.001). 
Yes 
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Table 2. Example of results reported for analyses related to race/ethnicity 
 
Results Significant 
difference based on 
race/ethnicity? 
Asian patients were not at an increased risk of PONV, despite 
being less likely to receive PONV prophylaxis (Supplemental 
Digital Content 1, table 3, http://links.lww.com/ALN/B260). 
No 
Covariates for this outcome included sex, race/ethnicity, 
education, 
income, and number of medical comorbidities. There was no 
significant effect of treatment, F(1,102) 5 1.55, P 5 0.216. 
Furthermore, the time by treatment interaction was not significant, 
F(2,207) 5 0.06, P 5 0.9376, nor were any interactions between the 
covariates and treatment condition. 
No 
Sex, race/ethnicity, and BMI were not significant moderators for 
any of the outcomes. 
No 
When age, gender, race, education, BMI, and treatment severity 
were added as covariates, the effect for psychological distress 
trended (p = .095) at post-treatment. The effect for satisfaction 
with health also trended (p = .083) at 6-month follow-up and was 
significant (p = .047) at 12-month follow-up. 
No 
Compared with White, Hispanics were associated with significant 
higher motor strength (P = 0.011), while Other patients (unknown 
ethnicity) were associated with significantly lower motor strength 
(P = 0.015).  
Yes 
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5. DISCUSSION  
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In this study we found that less than ten percent of analyzed randomized controlled 
trials reported results for sex-related analysis and one percent reported race/ethnicity-related 
analyses in their results. When trials included both women and men, and reported number of 
participants according to the sex, on average, there were more men included in trials, but with 
no major differences overall, as percent of women vs. men in trials was 51% vs. 49%, 
respectively. A quarter of trial authors used word gender instead of sex, and the majority of 
trials used words female and male, compared to women and men. In 38% of studies that 
reported outcomes for sex-related differences the study showed that there were significant 
differences between women and men for at least one outcome. 
Importance of the role of sex and ethnicity in pathology, diagnosis, prevention and 
treatment of various health conditions has been increasingly recognized as important in the 
scientific community. This increased attention to sex-related differences apparently has led to 
modest increase of inclusion of both sexes and reporting of sex-specific analyses in randomized 
controlled trials (RCTs). Analysis conducted in trials published in nine prominent medical 
journals in 2009 showed that median proportion of women in trials that included both men and 
women was 37% (12). In 2016 such analysis of trials published in two prominent journals 
showed that this proportion of women was 41% (13). In our study, we found that proportion of 
women was just slightly higher, i.e. 51%. 
A study of Geller et al. from 2011, analyzed RCTs published in nine prominent medical 
journals in 2009, and showed that 75% of trials did not have any outcome analyses based on 
sex (12). Avery et al. analyzed RCTs published in two journals with high impact, The Lancet 
and New England Journal of Medicine (NEJM), between April 1, 2016, and July 16, 2016. 
They found 60 trials, excluding nine that analyzed sex-specific conditions. They did not find a 
single trial that had pre-specified analysis of differences by sex (13). 
A study from 2017 of Welch et al. analyzed reporting about sex and/or gender in a 
sample of RCTs conducted in Canada on humans. The study showed that 98% of the trials they 
analyzed, described the demographics of the participants, while only 6% accompanied a 
subgroup about sex, whereas none of that trials reported any comprehensive analysis about sex 
or gender (23). 
Additionally, the authors reported about the terminology that was used to describe the 
patients’ demographic composition. The variations of using the term sex or gender was big, 
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while no RCT gave a definition of sex or gender. Likewise, none of the trials explained any 
intention to conduct or specify gender or sex analysis (23). 
In our study we did not analyze trial protocols, so we cannot make any conclusions 
about whether our included trials perhaps planned to do sex-specific analyses, but failed to 
report them subsequently. We only analyzed information that were available in a manuscript 
published in the analyzed journals. Based on our results, there were 32 trials that mentioned 
sex-based analyses in Methods, and 52 that reported any sex-related analyses. 
In the field of pain, influence of sex on experimentally-induced pain and pain sensitivity 
is still debated (14,15). However, insufficient attention to sex-related reporting in clinical trials 
about pain has been highlighted in recent literature. A systematic review about sex differences 
in the efficacy of psychological therapies for treatment of chronic and recurrent pain in children 
and adolescents found that not a single study published on this subject reported outcome data 
separately by sex. To obtain these data, authors of the systematic review contacted authors of 
46 included studies and authors of 17 studies provided requested data (16). The systematic 
review conclusion was that future studies need to examine whether mechanisms of treatment 
efficacy differ between sexes, and consider the impact of pre-treatment sex differences on 
response to treatment (16). 
Insufficient reporting of sex effects was also found for systematic reviews (SRs) about 
chronic pain (17). Duan-Porter et al. analyzed SRs on interventions for treatment of depression, 
type 2 diabetes mellitus, and chronic pain conditions, where pain conditions included chronic 
low back pain, knee osteoarthritis, and fibromyalgia. The study included SRs published since 
October 1st, 2009 that analyzed medications, behavioral interventions, exercise, quality 
improvement, and some condition-specific treatments. Reporting of sex effects by primary 
RCTs was also examined. Among 313 eligible SRs, including 86 for depression, 159 for type 
2 diabetes mellitus, and 68 for chronic pain, very few (n = 29) had reported any sex effects. 
Most SRs that reported any sex effects used type of analysis called meta-regression, whereas 
9 SRs used subgroup analysis or individual-patient data (IPD) meta-analysis (17). 
Furthermore, in the study of Duan-Porter et al, the proportion of SRs that reported the 
sex distribution of primary studies varied from 31% (n = 8) for low back pain to 68% (n = 23) 
for trials about fibromyalgia. Primary RCTs also seldom reported sex effects, and most did not 
have an adequate sample size to examine them. The authors concluded that all SRs should 
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report the proportion of women enrolled in primary studies as well as evaluate sex effects using 
relevant methods whenever power is adequate (17). 
Comparing this insufficient attention to sex-based analyses, previous studies have also 
described similar lack of attention to race/ethnicity in trials. A study of Geller et al. indicated 
that 21% of analyzed trials did not report race or ethnicity in their sample of participants, and 
64% did not report any analyses based on race/ethnicity (12). Likewise, multiple studies 
reported that race/ethnicity was associated with important differences between participants 
when it comes to pain (19-21). For this reason, race/ethnicity should be reported among the 
baseline characteristics of patients and, when feasible, outcomes should also be reported based 
on race/ethnicity so that we can gain more insight into potential differences in the effect of 
interventions related to race/ethnicity. 
In our study, 5 trials indicated in the Methods that they planned any race/ethnicity-
based analyses, and 8 reported such results in the Results, excluding those that reported number 
of participants of different race/ethnicity. Less than ten percent of trials reported race/ethnicity 
of participants, and in those studies 74% of participants were described as white or Caucasian. 
One of the reasons contributing to insufficient participation of non-white participants 
in clinical trials could be their unwillingness to engage in such activities. In a recent study, 
Pariera et al. explored willingness of people to participate in clinical trials by ethnicity. It was 
shown that indeed that there is a difference between ethnical groups in this respect. African-
Americans and Hispanic-Americans had more negative attitudes towards clinical trials than 
white/non-Hispanics. The factors that affected the willingness were questions about who 
profited from the clinical trial. White and non-Hispanics expressed higher willingness to 
participate in a clinical trial if the trial would extend their life. African-Americans and 
Hispanic-Americans indicated they were more likely to participate if the doctor would profit 
from the drugs being tested. Interestingly, white/ non-Hispanics were most interested if the 
pharmaceutical companies would take an advantage out of that trial (24). 
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6. CONCLUSIONS  
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Based on the study results, we can conclude the following: 
1. None of the analyzed trials stratified participants based on sex and race/ethnicity, 
2. Proportion of included women and men was similar; on average percent of included 
women was 49% and 51% for men, 
3. Less than 10% of analyzed trial reported information about participants’ ethnicity, 
4. Sex-related results were reported in 7.9% and race/ethnicity-related results were 
reported in 0.15% of analyzed trials, 
5. Of the 52 trials that reported sex-related results, 20 (38%) described that there was a 
significant difference between women and men in at least one analyzed outcome; 
among 8 trials that reported results based on race/ethnicity, 1 (12.5%) trial reported 
significant difference in at least one analyzed outcome for participants of different 
race/ethnicity 
6. Less than 5% of analyzed trials addressed sex/gender or race/ethnicity in Discussion. 
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8. SUMMARY  
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Aim: The aim of this study was to assess reporting of data on sex and race/ethnicity in 
randomized controlled trials (RCTs) of interventions published in the highest-ranking journals 
from the field of anesthesiology. 
Methods: We analyzed RCTs published from 2014 to mid-2017 in the seven journals 
belonging to the top 25% in the field of Anesthesiology according to the 2016 Journal Impact 
Factor published by the database Journal Citation Reports. We extracted data regarding 
terminology for sex/gender, proportion of participants according to the race/gender and 
race/ethnicity, and results shown for the race/gender and race/ethnicity. 
Results: Among the analyzed 657 trials, none stratified participants based on sex/gender or 
race/ethnicity. Proportion of included women and men was very similar. Most of the included 
participants were white/Caucasian. Less than 10% of analyzed trial reported information about 
participants’ ethnicity. Sex-related results were reported in 7.9% and race/ethnicity-related 
results were reported in 0.15% of analyzed trials. Of the 52 trials that reported sex-related 
results, 20 (38%) described that there was a significant difference between women and men in 
at least one analyzed outcome; among 8 trials that reported results based on race/ethnicity, 1 
(12.5%) trial reported significant difference in at least one analyzed outcome for participants 
of different race/ethnicity. Less than 5% of analyzed trials addressed sex/gender or 
race/ethnicity in Discussion. 
Conclusion: Sex-specific and race/ethnicity aspects are neglected in anesthesiology trials, even 
though on average these trials included similar number of women and men. Outcomes related 
to anesthesiology and pain may differ in participants related to sex and race/ethnicity. 
Therefore, trialists in the field of anesthesiology should invest more effort to plan, conduct and 
report sex--specific and race/ethnicity results. Predominant inclusion of white participants in 
anesthesiology trials should be reconsidered. 
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9. CROATIAN SUMMARY  
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Naslov istraživanja: Izvještavanje o spolu i rasi/etnicitetu u randomiziranim kontroliranim 
pokusima objavljenim u najboljim časopisima iz područja anesteziologije 
Cilj: Istražiti načine izvještavanja podatka o spolu i rasi/etnicitetu u randomiziranim 
kontroliranim pokusima objavljenim u najboljim časopisima iz područja anesteziologije. 
Metode: Analizirani su randomizirani kontrolirani pokusi objavljeni od 2014. do sredine 2017. 
godine u sedam časopisa koji se nalaze u 25% najboljih časopisa prema čimbeniku odjeka iz 
2016. Godine koji objavljuje baza Journal Citation Reports. Izvađeni su podatci izvještava o 
analizima nja podataka o spolu i rasi/etnicitetu. 
Rezultati: Analizirano je 657 pokusa. Niti jedan nije stratificirao ispitanike po spolu ili 
rasi/etnicitetu. Udio uključenih žena i muškaraca u prosjeku je bi podjednak. Većina uključenih 
ispitanika bili su bijelci. Manje od 10% uključenih radova opisalo je informacije o 
rasi/etnicitetu uključenih ispitanika. Rezultati koji se tiču analiza prema spolu objavljeni su u 
7,9%, a rezultati analiza ovisnih o rasi/etnicitetu u 0,15% uključenih pokusa. Među 52 pokusa 
koja su prikazala podatke ovisno o spolu, 20 (38%) je opisalo značajne razlike u barem jednom 
ishodu ovisno o spolu, a u 1 (12,5%) od 8 radova koji su prikazali analize ovisno o 
rasi/etnicitetu prikazane su razlike prema tom aspektu. Manje od 5% analiziranih pokusa 
spomenulo je spol ili rasu/etnicitet u Diskusiji. 
Zaključak: Klinički pokusi iz najboljih anestezioloških časopisa zanemaruj aspekte spola i 
rase/etniciteta. Rezultati se mogu razlikovati ovisno o tome kojeg je spola i rase/etniciteta 
ispitanik pa je nužno u budućim istraživanjima planirati, provesti i opisati takve rezultate. 
Također je nužno uložiti više truda u uključivanje osoba različite rase/etniciteta u kliničke 
pokuse. 
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